|Day's Range||27.51 - 27.51|
In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.
The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.
The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc. China has imposed a virtual lockdown on Wuhan and severely restricted travel in its wider province of Hubei and some other cities.
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Amgen saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 79 to 84. For the period ended Dec. 31, Amgen earned $3.64 per share, minus some items, on $6.2 billion in sales. Chief Executive Robert Bradway said in the earnings release that the company is entering what he called a new product-driven revenue era.
Shares of the pharmaceutical companies firm Bristol-Myers Squibb jumped 3% in premarket trading early Thursday after the company announced financial results for the last quarter of 2019 that blew past analyst expectations.
Survivors in Canada are Taking Steps to Reduce the Risk of Another Heart Attack. But is it Enough?
Amgen stock is facing concerns that its adjusted earnings will slide in 2020. Is it time to buy shares of the biotech company?
Shares of Reata Pharmaceuticals jumped Friday on reports suggesting Amgen could be interested in acquiring the smaller biotech company. Reata is working on a key kidney disease treatment.
Shares of Reata Pharmaceuticals soared Friday on rumors the clinical stage biopharmaceutical company might be acquired by drugmaking giant Amgen . Amgen, meanwhile, was falling 6.2% to $212.29, the worst performer on both the S&P 500 and the Nasdaq, after offering a weaker-than-expected outlook for the year. Investors apparently reacted when Amgen CEO Bob Bradway was discussing kidney medicine during the company's fourth-quarter earnings call.